{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:52:28Z","timestamp":1756993948922,"version":"3.40.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the national natural science foundation of china","doi-asserted-by":"crossref","award":["81501753"],"award-info":[{"award-number":["81501753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>To assess the clinical efficacy and safety of gelatin sponge microparticles-transcatheter arterial chemoembolization (GSMs-TACE) plus synchronous antigen-presenting dendritic cell (DC) sequential reinfusion for advanced large liver cancer (LC).<\/jats:p>\n            <jats:p>Patients with large LC were assigned to the experimental (combined sequential DC therapy) or control group. All patients received standardized GSMs-TACE. In the experimental group, 60\u200amL of peripheral blood was collected for in vitro culture of DCs (10\u201314\u200adays). Then, intravenous reinfusion was conducted 3 times within 10, 20, and 30\u200adays after surgery. Adverse reactions during the treatment were recorded and evaluated. The overall survival, transcatheter arterial chemoembolization frequency, and physical score (PS) were calculated.<\/jats:p>\n            <jats:p>The median survival time of the experimental group was significantly longer than that of the control group. There were significant differences in median progression-free survival between the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) and the objective effective rate at 1 and 6\u200amonths and 1\u200ayear (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05), but not 2\u200ayears (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.05). The PSs of 2 groups were significantly improved at 1\u200amonth after GSMs-TACE, with more obvious improvement in the experimental group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05).<\/jats:p>\n            <jats:p>GSMs-TACE plus synchronous DC sequential reinfusion significantly prolonged the median survival time, improved the tumor response rate and PS, prolonged progression-free survival, and reduced intervention frequency. GSMs-TACE plus synchronous DC sequential reinfusion treatment is suitable for comprehensive treatment of patients with advanced larger LC in China.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028803","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T13:14:16Z","timestamp":1645794856000},"page":"e28803","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Clinical application of gelatin sponge microparticles-transcatheter arterial chemoembolization combined with synchronous antigen-presenting dendritic cell sequential reinfusion for treatment of advanced large liver cancer"],"prefix":"10.1097","volume":"101","author":[{"given":"Guang Sheng","family":"Zhao","sequence":"first","affiliation":[{"name":"Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian University, No.6 Jie Fang Street, Dalian, Liaoning Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[{"name":"Interventional Medicine Center, Linyi Cancer Hospital, 6 East Lingyuan Street, Linyi, Shandong Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Pancreatic Center, Beijing Tsinghua Changgung Hospital, 168 Litang Road, Changping District, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[{"name":"Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian University, No.6 Jie Fang Street, Dalian, Liaoning Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Treatment Center, Affiliated Zhongshan Hospital of Dalian University, No.6 Jiefang Street, Dalian, Liaoning Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, No.467 Zhongshan Road, Shahekou District, Dalian 116027, Liaoning Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui Ping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Zhongshan Hospital of Dalian University, No.6 Jie Fang Street, Dalian, Liaoning Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0171-9263","authenticated-orcid":false,"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian University, No.6 Jie Fang Street, Dalian, Liaoning Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Pancreatic Center, Beijing Tsinghua Changgung Hospital, 168 Litang Road, Changping District, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyong Milan Criteria: a RCT","volume":"61","author":"Yin","year":"2014","journal-title":"J Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.intimp.2014.07.019","article-title":"Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.intimp.2016.09.015","article-title":"TACE Combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"40","author":"He","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis","volume":"48","author":"Facciorusso","year":"2016","journal-title":"Dig Liver Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"72613","DOI":"10.18632\/oncotarget.19997","article-title":"Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy","volume":"8","author":"Schicho","year":"2017","journal-title":"Oncotarget"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jvir.2015.07.017","article-title":"A single-center retrospective comparison of doxorubicin-loaded hepasphere transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma","volume":"26","author":"Kucukay","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00261-016-0900-y","article-title":"Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization","volume":"42","author":"Morimoto","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"R10-20250504","first-page":"637","article-title":"Therapeutic effect of gelatin sponge microparticles via transcatheter arterial chemoembolization on primary liver cancer","volume":"21","author":"Zhang","year":"2013","journal-title":"Chin J Hepatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e7589","DOI":"10.1097\/MD.0000000000007589","article-title":"Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma Safety and efficacy","volume":"96","author":"Zhao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.24149","article-title":"Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma","volume":"53","author":"Mizukoshi","year":"2011","journal-title":"Hepatology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.21147\/j.issn.1000-9604.2018.01.01","article-title":"Cancer incidence and mortality in China, 2014","volume":"30","author":"Chen","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.ejca.2006.06.007","article-title":"Hepatitis B- and C-related hepatocellular arcinomas yield different clinical features and prognosis","volume":"42","author":"Chen","year":"2006","journal-title":"Eur J Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e6629","DOI":"10.1097\/MD.0000000000006629","article-title":"350-560\u03bcm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: the safety and efficacy","volume":"96","author":"Zhao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1007\/s13277-014-2408-9","article-title":"Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumour Biol"},{"key":"R18-20250504","first-page":"549","article-title":"Clinical experience of GSPs-TACE in treatment of hepatocellular carcinoma with blood-rich portal carcinoma","volume":"94","author":"Liu","year":"2014","journal-title":"Natl Med J China"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3892\/etm.2016.3573","article-title":"Gelatin sponge microparticles for the treatment of spontaneous rupture of hepatocellular carcinoma hemorrhage","volume":"12","author":"Wu","year":"2016","journal-title":"Exp Ther Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"Pawlik","year":"2011","journal-title":"J Clin Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2036.2011.04697.x","article-title":"The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma","volume":"4","author":"Cabrera","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"48","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd.2018.146","article-title":"The hepatocellular carcinoma market","volume":"18","author":"Dawkins","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10637-018-0636-3","article-title":"Aphase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma","volume":"37","author":"Ikeda","year":"2019","journal-title":"Invest New Drugs"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2018.36.15_suppl.4076","article-title":"A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)","volume":"36","author":"Ikeda","year":"2018","journal-title":"J Clin Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"624789","DOI":"10.3389\/fimmu.2021.624789","article-title":"Changes in the peripheral blood Treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles","volume":"12","author":"Ren","year":"2021","journal-title":"Front Immunol"},{"key":"R27-20250504","first-page":"744","article-title":"Changes of vascular endothelial growth factor level in peripheral blood in hepatocellular carcinoma patients after TACE with gelatin sponge particles","volume":"9","author":"Zhang","year":"2012","journal-title":"Chin J Interv Imaging Ther"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"7132158","DOI":"10.1155\/2016\/7132158","article-title":"Neuropilin-1highCD4+CD25+ regulatory t cells exhibit primary negative immunoregulation in sepsis","volume":"2016","author":"Gao","year":"2016","journal-title":"Mediators Inflamm"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"24249","DOI":"10.1038\/srep24249","article-title":"Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2174\/0929867311320110006","article-title":"Myeloid derived suppressor cells and their role in diseases","volume":"20","author":"Kong","year":"2013","journal-title":"Curr Med Chem"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid- derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.mehy.2014.08.022","article-title":"Effective activity of cytokine induced killer cells against hepatocellular carcinoma including tumor-initiating cells","volume":"84","author":"Rong","year":"2015","journal-title":"Med Hypotheses"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/15384047.2018.1433501","article-title":"A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE","volume":"19","author":"Zhang","year":"2018","journal-title":"Cancer Biol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:22:20Z","timestamp":1746328940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028803"}},"subtitle":["A single-center, prospective, non-randomized, controlled trial"],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028803","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"2021-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}